Peel Hunt reissued their under review rating on shares of Motif Bio (LON:MTFB) in a research report sent to investors on Tuesday, ThisIsMoney.Co.Uk reports.
Shares of Motif Bio stock opened at GBX 7.86 ($0.10) on Tuesday. The firm has a market cap of $26.92 million and a price-to-earnings ratio of -1.09. Motif Bio has a 1-year low of GBX 4.75 ($0.06) and a 1-year high of GBX 44.90 ($0.59).
About Motif Bio
Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis.
Recommended Story: Momentum Indicator: Relative Strength Index
Receive News & Ratings for Motif Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio and related companies with MarketBeat.com's FREE daily email newsletter.